Intraportal serotonin infusion enhances net hepatic glucose uptake (NHGU) during glucose infusion but blunts nonhepatic glucose uptake and can cause gastrointestinal (GI) discomfort and diarrhea at high doses. Whether the serotonin precursor 5-hydroxytryptophan (5-HTP) could enhance NHGU without GI side effects during glucose infusion was examined in conscious 42-h-fasted dogs, using arteriovenous difference and tracer ([3- 
INTRODUCTION
Poor postprandial glycemic control is associated with elevated rates of all-cause mortality in individuals with type 2 diabetes (45), and thus control of postprandial hyperglycemia is an attractive pharmaceutical target. Intraportal infusion of serotonin (5-hydroxytryptamine or 5-HT) enhances net hepatic glucose uptake (NHGU) in the hyperinsulinemic, hyperglycemic conscious dog (28), indicating that 5-HT might be effective in reducing postprandial hyperglycemia.
However, elevated circulating 5-HT is associated with intestinal cramping and diarrhea (3).
Thus, for potential therapeutic use, agents that raise tissue levels of 5-HT without elevating blood 5-HT excessively are desirable.
Intraperitoneal administration of 5-hydroxytryptophan (5-HTP), the immediate precursor of 5-HT, has a hypoglycemic effect in mice, which is apparently related to intrahepatic ) was replaced intraportally in basal amounts. In addition, a primed, continuous variable rate infusion of 50% dextrose was begun through a peripheral vein, to maintain the hepatic glucose load 2-fold basal.
During P1, all dogs received intraportal normal saline infusion. At the end of P1, the dogs were divided into 2 groups. In the SAL group (n = 7), the intraportal saline infusion continued for the remainder of the study. In the HTP group (n = 6), 5-HTP was infused into the portal vein at 10, 20 , and 40 µg kg during P2, P3, and P4, respectively. The infusion rates were the same as the infusion rates for 5-HT in our previous study (28) . The portal route of infusion was chosen in order to target the 5-HTP at the liver as much as possible. In addition, we did not administer an inhibitor of peripheral aromatic L-amino acid decarboxylase (AADC). An AADC inhibitor would have reduced the conversion of 5-HTP to 5-HT in peripheral tissues, making more 5-HTP available to cross the blood-brain barrier (10). The liver has relatively high levels of AADC (21, 44) and thus should synthesize substantial amounts of 5-HT from the substrate.
Femoral artery, portal vein, and hepatic vein blood samples were taken every 15-30 min throughout the study as previously described (36). Arterial blood samples were also taken every 5 min throughout the experimental period to monitor the glucose level (36). After completion of each experiment, the animal was euthanized with an overdose of pentobarbital.
Processing and analysis of samples. Hematocrit; blood glucose, lactate, and glycerol; and plasma glucose, nonesterified fatty acids (NEFA), insulin, glucagon, cortisol, catecholamines and [ determined on whole blood by an HPLC-amperometric assay (38) with a CV of 4% as previously reported (28). Plasma leptin concentrations were analyzed by a sandwich ELISA assay using an anti-canine leptin antibody as previously described (20) , with inter-and intraassay CV < 4%. Plasma adiponectin was measured using a commercial mouse/rat ELISA kit (Otsuka Pharmaceuticals, Tokushima, Japan) optimized for analysis of canine samples, with intra-assay CV of 6.7-8.5% and inter-assay CV of 3.4-7.5% (35).
Calculations and data analysis. Hepatic blood flow was measured using ultrasonic flow probes and by use of ICG extraction. The two methods yielded similar results, but the data reported here were calculated with the ultrasonic-determined flows, because their measurement did not require an assumption regarding the relative contribution of arterial and portal flow to total hepatic blood flow.
The rate of glucose delivery to the liver, or hepatic glucose load; net hepatic substrate balance (NHB); net hepatic fractional substrate extraction; net hepatic carbon retention; hepatic sinusoidal insulin and glucagon concentrations; and nonhepatic glucose uptake (nonHGU) were calculated as described previously (33). During the 1 st h of glucose infusion, the nonHGU was corrected for the glucose required to fill the pool, using a pool fraction of 0.65 (6) and assuming that the volume of distribution for glucose equaled the volume of the extracellular fluid, or ~22% of the dog's weight (43). For all glucose balance calculations, glucose concentrations were converted from plasma to blood values by using correction factors (ratio of the blood to the plasma concentration) as previously established in our laboratory (18) . Hepatic glucose uptake (in dpm ) was calculated as was net hepatic glucose uptake, except that tritiated glucose measurements were used. The results were divided by the inflowing glucose specific activity (dpm/Imol glucose). Glucose R a and R d were calculated with a 2-compartment model using dog parameters as previously described (7, 25). The plasma insulin levels increased ~3-to 4-fold and remained stable during P1-P4 in both groups (Table 1) . Arterial and hepatic sinusoidal plasma glucagon concentrations were basal and indistinguishable in both groups throughout the experiments (Table 1) .
Arterial plasma cortisol concentrations remained basal in SAL throughout P1-P4. In HTP, the mean cortisol concentrations remained statistically unchanged from basal during P1-P4, but one animal did demonstrate a substantial increase from basal (84 to 271 nmol/l) during P4. This dog also exhibited a rise in arterial 5-HT concentrations to nearly 3-fold basal, as compared with the 40% increase observed in the other five dogs in the HTP group. Arterial plasma concentrations of epinephrine and norepinephrine did not change significantly during P1-P4 in either group (Table 1) .
Plasma leptin and adiponectin concentrations were available on four animals in each group. The concentrations of both hormones were similar during the basal period in the two groups, and they did not change significantly during the study in either group (Table 2) .
Hepatic blood flow, blood glucose concentrations, and hepatic glucose load. Portal vein blood flow decreased modestly in both groups during P1 as a response to somatostatin infusion (Table 3 ) and did not change significantly thereafter. There was a concomitant increase in hepatic artery flow. As a consequence, total hepatic blood flow was relatively stable throughout the experiments, with no differences between groups at any time.
Arterial blood glucose levels in SAL increased from a basal value of 4.6±0.1 mmol/l to 9.3±0.1 mmol/l during all experimental periods ( Fig. 1 ). In HTP, the arterial glucose concentration increased from 4.3±0.2 mmol/l to 9.0±0.1 mmol/l. There were no significant differences between groups. In addition, the hepatic glucose loads were not significantly different between groups at any time ( Net hepatic glucose balance, net hepatic fractional glucose extraction, and endogenous glucose R a . The groups exhibited a similar rate of net hepatic glucose output during the basal period. Coincident with the start of the experimental period, they switched from net production to net uptake, with the rates being no different between groups during P1 and P2 (Fig. 2) . In both groups NHGU during P2 averaged 18.5Imol respectively), but it increased in HTP (0.084 ± 0.014 and 0.110 ± 0.014 during P3 and P4, respectively; P < 0.05 vs SAL during P4). The rate of unidirectional (tracer-determined) hepatic glucose uptake did not differ significantly between groups during any period, although there was a tendency (P = 0.07) for it to be greater in HTP vs SAL during P4 (Table 4) , P < 0.005; Table 4 ).
Endogenous glucose R a decreased similarly in response to hyperglycemia and hyperinsulinemia in both groups (from 14.8 ± 1.0 to 3.4 ± 1.3 Imol Total and nonhepatic glucose disposal. The glucose infusion rate in both groups increased steadily in a time-dependent manner during P1-P4, with no differences between groups (45.0 ± 5.3, 55.2 ± 7.4, 60.6 ± 6.9, and 73.7 ± 11.6 Imol (Table   4 ) and nonhepatic glucose uptake ( Lactate metabolism and net hepatic carbon retention. Basal arterial blood lactate concentrations were significantly higher in SAL than HTP, but both groups demonstrated a significant increase in lactate levels in response to hyperglycemia and hyperinsulinemia (Table   FINAL ACCEPTED VERSION E-00614-2004.R1 10 5). The lactate concentrations continued to be lower in HTP than SAL throughout the study, but this did not reach statistical significance during P1 and P4. Both groups demonstrated a switch from net hepatic lactate uptake to output at the onset of the experimental period, and the rates in the two groups did not differ significantly at any time.
The rates of net hepatic carbon retention in SAL and HTP were similar during P1 and P2 (11.6 ± 1.9 and 17.0 ± 2.7 Imol ).
Glycerol and nonesterified fatty acid metabolism. Arterial glycerol concentrations were reduced ~55-65% by hyperglycemia and hyperinsulinemia in both groups, and net hepatic glycerol uptake fell in parallel with the glycerol levels, remaining suppressed throughout the experimental period (Table 5) . Arterial NEFA concentrations and net hepatic NEFA uptake changed in a manner similar to glycerol, decreasing ~80-90% during P1 in both groups and then remaining low throughout the remainder of the experimental period. , NHGU increased 29% and 40%, respectively, over the corresponding rates in SAL (P < 0.05 for both increments). By the end of the experimental period, NHGU in HTP had increased 68% over the rate during P1 (P < 0.05 vs the increase in SAL). Tracer measurements confirmed that there was a significant
and there was a strong tendency for hepatic glucose uptake to differ between groups during P4.
Similar to NHGU, net hepatic carbon retention was virtually identical between the groups during P1 and P2. During P3 and P4, net hepatic carbon retention was 31% and 50%, respectively, greater in HTP than in SAL (P < 0.05 for both). In this initial study we merely wanted to determine whether 5-HTP, given at any rate that would bring about 5-HT concentrations in the physiologic range, would induce NHGU. Therefore we administered 5-HTP in three increasing steps during P2-P4. As a result it is not possible to separate the effects of time from those of dosage. Nevertheless, it is possible to conclude definitively that 5-HTP impacted NHGU, hepatic glucose uptake, and hepatic carbon retention.
The effects of 5-HTP on the liver could have resulted either from a direct effect of 5-HT or from a secondary signal initiated elsewhere. In regard to a potential direct effect of 5-HT on hepatocytes, the liver contains AADC enzyme for conversion of 5-HTP to 5-HT, and this is enzyme is reported to have high efficiency at physiologic substrate concentrations (13).
Moreover, the 5-HT 2B receptor is known to be expressed in greatest abundance in the liver and kidney in humans (4), and isoforms of the 5-HT 3 receptor are also expressed in the human liver Another possible mechanism for the action of 5-HTP is via stimulation of the release of other hormones such as leptin (46, 47), which impacts upon insulin signaling and sensitivity in the liver (19, 22) , or adiponectin (48), a hormone with insulin sensitizing actions (49). Therefore, we measured these hormones in a subset of animals from each group. We were unable to identify any consistent changes related to 5-HTP administration, although we cannot rule out the possibility that 5-HTP increases the binding of leptin to its soluble receptor, thereby modulating its actions (5).
Because 5-HTP infusion was associated with a similar rate of nonhepatic glucose uptake between groups but an enhancement of liver glucose uptake during P3 and P4, there was a tendency for whole body glucose disposal to be increased in the HTP group during those two periods. This tendency was evidenced in both the glucose infusion rate (~6-8 Imol min -1 greater in HTP than SAL during P3 and P4), but neither parameter was statistically different between the groups (P = 0.4 for both). We have previously observed under a variety of conditions (e.g., 1, 9, 27, 29) that when NHGU is enhanced, there is a reciprocal reduction in nonhepatic (primarily skeletal muscle) glucose uptake, such that there is little impact on whole body glucose disposal.
While the lack of reciprocity in the current study may simply have resulted from difficulty in observing a small change against the background of a high rate of nonhepatic glucose uptake, it deserves further examination in the future. Impaired splanchnic (primarily liver) glucose uptake in response to glucose feeding is one of the defects associated with type 2 diabetes (2). We studied 5-HTP with the goal of determining whether it would be effective in increasing the proportion of a carbohydrate load extracted by the liver, thereby reducing the load to be disposed of in the peripheral tissues. Thus, we did not expect 5-HTP to alter total body uptake.
Nevertheless, the current data suggest that an optimal dosage or form of 5-HTP, or a related agent, might increase total glucose disposal.
This reciprocity of tissue glucose uptake (liver vs muscle) was evident during 5-HT infusion at 20 and 40 Ig·kg ). This agrees with previous data demonstrating that chronic elevation of cortisol brings about peripheral insulin resistance and markedly enhances NHGU (12), but acute elevations of cortisol have no such effect (11).
In conclusion, intraportal infusion of 5-HTP enhanced NHGU without blunting nonhepatic glucose disposal under hyperglycemic, hyperinsulinemic conditions. We did not examine the effects of peripheral 5-HTP infusion, and thus it is not possible to speculate whether the effects observed were specific to the intraportal route of delivery. There were no significant increases in cortisol or catecholamines during 5-HTP delivery, and the dogs evidenced no diarrhea or signs of distress. Thus, 5-HTP or related agents may provide a tool for reducing the proportion of the glucose load that must be disposed of in the peripheral tissues postprandially in individuals with type 2 diabetes or impaired glucose tolerance. Values are means ± SE. SAL dogs (n = 7) received intraportal saline infusion during P1-P4; HTP dogs (n = 6) received saline during P1 and intraportal 5-HTP at 10, 20, and 40 Ig There were no significant differences between groups. , respectively, during P3 and P4. There were no significant differences between groups. Values are means ± SE. SAL dogs (n = 7) received intraportal saline infusion during P1-P4; HTP dogs (n = 6) received saline during P1 and intraportal 5-HTP at 10, 20, and 40 Ig , respectively, during P2-P4.
There were no significant differences between groups; P = 0.07 between groups for HGU during P4. glucose infusion to double the hepatic glucose load, and intraportal infusion of 5-HTP (HTP group; n = 6) at the rates shown or saline (SAL; n = 7). There were no significant differences between groups. of study conditions. There were no significant differences between groups. 
